Infection with adenovirus, a common childhood virus, is the leading hypothesis for recent cases of severe hepatitis of unknown origin in children that have led to at least six deaths, U.S. health officials said on May 20.
AstraZeneca’s Phase III Provent trial results showed a statistically significant 77 percent decrease in a patient’s likelihood of developing symptomatic COVID-19 when proactively treated with Evusheld. Additionally, results were announced by Clover Biopharmaceuticals for the Phase II/III Spectra global study investigating the efficacy of the SCB-2019 (CpG 1018/Alum) vaccine booster in patients that have previously developed a COVID-19 infection.
A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
The Biden administration on Wednesday launched a new website to provide a clearinghouse of information on COVID-19 as part of a continuing effort to prepare Americans to live with the coronavirus.
The U.S. Centers for Disease Control and Prevention (CDC) on March 29 updated its recommendation to allow certain immunocompromised individuals and people over the age of 50 to receive an additional booster dose of COVID-19 vaccines.
The U.S. Food and Drug Administration will weigh the benefits of authorizing a round of boosters of either the Pfizer/BioNTech or Moderna COVID-19 vaccine to a broader population in the fall, a top official said on March 29.
Without holding a meeting of its vaccines advisory committee, the U.S. Food and Drug Administration (FDA) authorized a fourth shot of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 50 years of age and older.
The World Health Organization indicated WHO is tracking four Omicron subvariants: BA.1, BA.1.1, BA.2 and BA.3. BA.2 has a growth advantage over BA.1, the variant responsible for the recent Omicron surge.
The COVID-19 pandemic that became evident in the United States in early 2020 had a profound and disruptive effect upon cancer research and treatment, but the lessons learned can be used to improve healthcare delivery in multiple indications, according to the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care that was released February 9th.
Covid-19 antibodies passed from infected mothers to their breastfeeding newborns provide more benefit to the baby than researchers expected to see, according to a report published on November 3 in JAMA Network Open. In other research, among people with impaired immune systems, some get less benefit than others from the mRNA Covid-19 vaccines while new data help clarify the differences and supports the need for extra shots.